DOCKET NO: 220243US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :

STEPHEN ARKINSTALL, ET AL. : EXAMINER: DAVIS, ZINNA

NORTHINGTON

SERIAL NO: 10/088,074

FILED: OCTOBER 13, 2004 : GROUP ART UNIT: 1625

FOR: PHARMACEUTICALLY ACTIVE SULFONYL HYDRAZIDE DERIVATIVES

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Election/Restriction Requirement dated June 28, 2007, Applicants elect, with traverse, Group I, Claims 1-9 and 17-26, for examination.

As a single disclosed specie, for examination purposes only, Applicants elect:

N-[(5-{[3-chloro-5-(trifluoromethyl)pyridine-2-

 $yl] amino \} but an oyl) hydrazine] sulfonyl \} thien-2-yl) methyl] -4-fluoroben zamide$

(Compound 32 on page 42 in the specification)